Vicki L. Goodman, M.D. is chief medical officer at Mural Oncology.
Dr. Goodman previously served as executive vice president, product development & medical affairs, and chief medical officer of Exelixis, Inc., a publicly-traded biopharmaceutical company. Prior to Exelixis, Dr. Goodman was vice president, clinical research and therapeutic area head, late stage oncology of Merck & Co., Inc. Dr. Goodman was a member of the oncology senior leadership team at BMS, most recently as vice president and head, new asset development teams. She held positions of increasing responsibility at GlaxoSmithKline plc.
Prior to entering the biopharmaceutical industry, she worked as a Medical Officer in the then-Division of Oncology Drug Products, part of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration. Dr. Goodman completed a clinical fellowship in hematology and medical oncology at the University of Michigan, Ann Arbor, where she also undertook her internship and residency.
Dr. Goodman obtained her M.D. from Albert Einstein College of Medicine and her B.A. in Biochemistry, with Honors, from Rutgers University.